Important Class Action for BioAge Investors
The Gross Law Firm has an important message for all shareholders of BioAge Labs, Inc. (NASDAQ: BIOA) regarding a pending class action lawsuit. Investors who acquired shares of BIOA during the defined class period are being called to engage with the firm regarding the potential lead plaintiff appointment.
Who Should Get Involved?
This is a significant opportunity for everyone who purchased shares of BioAge. If you bought shares according to the class period linked to the company's registration statement for the public offering, it is advisable to reach out to the Gross Law Firm. Involvement in this class action does not necessitate being a lead plaintiff to participate in any potential recovery.
Details on the Class Period and Allegations
The class action lawsuit covers all shareholders who acquired stock related to BioAge's initial public offering around September 26, 2024. The allegations are serious: on December 6, 2024, the company announced the termination of its STRIDES Phase 2 trial for azelaprag, a lead product candidate. This announcement was shocking, given how the firm had previously emphasized the medication's promise in treating patients using incretin drugs. Following the announcement, BioAge's stock price plummeted from $20.09 on the day of the announcement to $4.65 the following day.
Key Dates and Actions for Shareholders
The deadline for shareholders to act is set for March 10, 2025, which is fast approaching. Those impacted are encouraged to register for participation in this class action quickly. By registering your details, you will be incorporated into portfolio monitoring software that provides updates through the case's progress. It is important to note that there is no cost or obligation associated with joining this legal effort.
Why Choose The Gross Law Firm?
So, why consider The Gross Law Firm? This nationally recognized class action law firm prioritizes protecting investors' rights affected by deceptive and illegal business practices. The firm is dedicated to holding companies accountable for adherence to ethical business practices and corporate responsibility. The Gross Law Firm is particularly focused on seeking compensation for investors who have suffered losses due to misleading statements or omissions by companies, which artificially inflated stock prices. Their dedication is evident, as they navigate the complexities of securities law to advocate for shareholders.
Contact Information
The Gross Law Firm encourages all interested shareholders to reach out for more information. They are located at 15 West 38th Street, 12th floor, New York, NY 10018. You can contact them by phone at (646) 453-8903 for further assistance.
Frequently Asked Questions
What is the class action about?
The class action concerns BioAge Labs’ stock performance and allegations regarding significant safety concerns associated with its product, azelaprag.
Who is eligible to participate?
Shareholders who purchased BioAge shares during the specified class period are eligible to participate.
What is the deadline for action?
The deadline for shareholders to register for participation is March 10, 2025.
Are there any costs to join the lawsuit?
No, there is no cost or obligation to participate in the class action.
How will I be informed about the case's progress?
Once registered, you will receive updates through portfolio monitoring software about the status of your case.
